Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs
Open accessThe DOI matches its Crossref record; 330 of the 330 references it cites were found in a registry or an index.
Abstract
Macrophages are ancient, phagocytic immune cells thought to have their origins 500 million years ago in metazoan phylogeny. The understanding of macrophages has evolved to encompass their foundational roles in development, homeostasis, tissue repair, inflammation, and immunity. Notably, macrophages display high plasticity in response to environmental cues, capable of a strikingly wide variety of dynamic gene signatures and phenotypes. Macrophages are also involved in many pathological states including neural disease, asthma, liver disease, heart disease, cancer, and others. In cancer, most tumor-associated immune cells are macrophages, coined tumor-associated macrophages (TAMs). While some TAMs can display anti-tumor properties such as phagocytizing tumor cells and orchestrating an immune response, most macrophages in the tumor microenvironment are immunosuppressive and pro-tumorigenic. Macrophages have been implicated in all stages of cancer. Therefore, interest in manipulating macrophages as a therapeutic strategy against cancer developed as early as the 1970s. Companion dogs are a strong comparative immuno-oncology model for people due to documented similarities in the immune system and spontaneous cancers between the species. Data from clinical trials in humans and dogs can be leveraged to further scientific advancements that benefit both species. This review aims to provide a summary of the current state of knowledge on macrophages in general, and an in-depth review of macrophages as a therapeutic strategy against cancer in humans and companion dogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“engineered CAR-Ms have leaded to increase of anti-tumor cytokines, such as IL-6, and chemokines, such as CXCL18, in the TME of osteosarcoma [138, 139].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [138]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190 · cited 1×
“There are numerous populations of TRMs that are singularly adapted to their anatomical location and unique in their ability to self-renew through proliferation (31, 32).”
BackgroundMacrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188 · cited 2×
“They contribute to the initiation of cancer through smoldering inflammation, leading to a mutagenic environment (9, 10).”
BackgroundThe M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Macrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684 · cited 2×
“Macrophages are also involved in a variety of pathological states including neural disease, asthma, liver disease, heart disease, cancer, and others (6).”
BackgroundmRNA-Seq whole-transcriptome analysis of a single cell
Tang, F., Barbacioru, C., Wang, Y., Nordman, E., Lee, C., Xu, N., Wang, X., Bodeau, J., Tuch, B. B., Siddiqui, A., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1315 · Cited by 3,969
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287 · cited 1×
“It was noted that IFN-g and lipopolysaccharide (LPS) could activate macrophages in the Th1 strains to produce nitrous oxide more easily, while LPS activated arginine macrophage metabolism in the Th2 strains (52).”
BackgroundMurray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981 · cited 3×
“A more comprehensive outline of the history of macrophage research is presented in several good reviews (15, 29).”
BackgroundIDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
Steinman, R. M., & Cohn, Z. A. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.137.5.1142 · Cited by 2,424
Hashimoto, D., Chow, A., Noizat, C., Teo, P., Beasley, M. B., Leboeuf, M., Becker, C. D., See, P., Price, J., Lucas, D., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.04.004 · Cited by 2,311
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Orecchioni, M., Ghosheh, Y., Pramod, A. B., & Ley, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01084 · Cited by 2,063
The metabolic signature of macrophage responses
Viola, A., Munari, F., Sánchez-Rodríguez, R., Scolaro, T., & Castegna, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01462 · Cited by 2,021 · cited 5×
“Function Infectious/Th1 response, type 1 inflammation, intracellular pathogen killing, tumor resistance (46, 54, 60) Allergy/Th2 response, parasite killing, immunoregulation, matrix deposition, tissue repair, tumor promotion (46, 54, 60)”
BackgroundInfluentialthe Immunological Genome Consortium, Gautier, E. L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2419 · Cited by 1,972 · cited 1×
“Regardless of their remarkable diversity, a few core genetic programs establish macrophages’ key role as phagocytes (3, 4).”
BackgroundNathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
Stein, M., Keshav, S., Harris, N., & Gordon, S. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.1.287 · Cited by 1,960
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Tumor-Associated Macrophages in Tumor Immunity
Pan, Y., Yu, Y., Wang, X., & Zhang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583084 · Cited by 1,872 · cited 2×
“Although initial ly aligned most strongly with tumor-associated inflammation, it is now known that TAMs interact with cancer cells, other immune cells, and stromal cells to facilitate several other hallmarks of cancer (10, 93).”
BackgroundMacrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · cited 2×
“acids, and lipids increases the availability of critical nutrients such as iron in the TME, contributes to immunosuppression, and provides strong growth signals to cancer cells (55, 104).”
BackgroundMacrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769 · cited 2×
“Although initial ly aligned most strongly with tumor-associated inflammation, it is now known that TAMs interact with cancer cells, other immune cells, and stromal cells to facilitate several other hallmarks of cancer (10, 93).”
BackgroundUnderstanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms
Rőszer, T. (2015) · Mediators of Inflammation · doi:10.1155/2015/816460 · Cited by 1,762
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Elgueta, R., Benson, M. J., De Vries, V. C., Wasiuk, A., Guo, Y., & Noelle, R. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00782.x · Cited by 1,625
A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells
Cheng, S., Li, Z., Gao, R., Xing, B., Gao, Y., Yang, Y., Qin, S., Zhang, L., Ouyang, H., Du, P., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.010 · Cited by 1,601 · cited 3×
“Single-cell RNA-seq (scRNA-seq) techniques, first reported in 2009, have made incredible progress in elucidating the complexity of TAMs a priori (91, 149, 150).”
BackgroundMethodHonigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationHuman chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,451
Lin, Y., Xu, J., & Lan, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0760-3 · Cited by 1,398
The cellular and molecular origin of tumor-associated macrophages
Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., Pamer, E. G., & Li, M. O. (2014) · Science · doi:10.1126/science.1252510 · Cited by 1,393 · cited 1×
“Additionally, TAM maturation has been shown as distinct from typical alternative activation of macrophages (92).”
BackgroundCD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,385
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
van Furth, R., Cohn, Z. A., Jg, H., Humphrey, J., Spector, W. G., & Langevoort, H. L. (1972) · PubMed Central · Cited by 1,133
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807315 · Cited by 1,126
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
A Clonogenic Bone Marrow Progenitor Specific for Macrophages and Dendritic Cells
Fogg, D. K., Sibon, C., Miled, C., Jung, S., Aucouturier, P., Littman, D. R., Cumano, A., & Geissmann, F. (2006) · Science · doi:10.1126/science.1117729 · Cited by 1,053 · cited 1×
“A bone marrowderived progenitor cell of monocytes, macrophages and DCs was isolated in 2006 in the mouse, although this finding has since been debated in favor of the theory that there is not a common macrophage-dendritic cell precursor (22, 23).”
BackgroundZhang, Q.-W., Liu, L., Gong, C.-Y., Shi, H.-S., Zeng, Y.-H., Wang, X.-Z., Zhao, Y.-W., & Wei, Y.-Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050946 · Cited by 1,039
Role of Matrix Metalloproteinases in Angiogenesis and Cancer
Quintero-Fabián, S., Arreola, R., Becerril-Villanueva, E., Torres-Romero, J. C., Arana-Argáez, V., Lara-Riegos, J., Ramírez-Camacho, M. A., & Alvarez-Sánchez, M. E. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01370 · Cited by 1,036 · cited 1×
“For example, TAMs produce matrix metalloproteinases and cathepsins, which disrupt cell junctions and basement membranes to aid in tumor invasion into surrounding tissues and blood vessels (99, 100).”
BackgroundColony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,020
Hiratsuka, S., Watanabe, A., Aburatani, H., & Maru, Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1507 · Cited by 1,015 · cited 1×
“Another interesting example demonstrates that primary tumor secretion of factors such as vascular endothelial growth factor-A and transforming growth factor-beta induce distant lung endothelium to produce a variety of monocyte chemoattractants, thus preparing the metastatic niche (101).”
BackgroundDevelopmental and Functional Heterogeneity of Monocytes
Guilliams, M., Mildner, A., & Yona, S. (2018) · Immunity · doi:10.1016/j.immuni.2018.10.005 · Cited by 973 · cited 1×
“It should be noted that monocytes themselves have been recognized as increasingly heterogeneous in origin and function, with multiple defined subsets (26, 27).”
BackgroundCassetta, L., Fragkogianni, S., Sims, A. H., Swierczak, A., Forrester, L. M., Zhang, H., Soong, D. Y. H., Cotechini, T., Anur, P., Lin, E. Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.009 · Cited by 920
Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases
Kapellos, T. S., Bonaguro, L., Gemünd, I., Reusch, N., Saglam, A., Hinkley, E. R., & Schultze, J. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02035 · Cited by 890 · cited 1×
“Monocyte-derived macrophages (MDMs) are continually renewed via the bone marrow and spleen during periods of high demand such as inflammation or tissue reparation (28, 30).”
BackgroundRole of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Biochemical and functional characterization of three activated macrophage populations
Edwards, J. P., Zhang, X., Frauwirth, K. A., & Mosser, D. M. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0406249 · Cited by 863
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.040 · Cited by 852
New insights into the multidimensional concept of macrophage ontogeny, activation and function
Ginhoux, F., Schultze, J. L., Murray, P. J., Ochando, J., & Biswas, S. K. (2016) · Nature Immunology · doi:10.1038/ni.3324 · Cited by 833 · cited 1×
“It is easy to see that these dichotomous labels fall short of capturing the complexity of macrophage reality, which is best described as a multidimensional spectrum (61).”
BackgroundMacrophage Polarization in Physiological and Pathological Pregnancy
Yao, Y., Xu, X.-H., & Jin, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00792 · Cited by 825 · cited 5×
“Transcription factors STAT1, IRF5, NF-kB (46, 59) STAT6, IRF4, PPAR (46, 59)”
InfluentialMesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophages
Kim, J., & Hematti, P. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.09.004 · Cited by 785
Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity
Ringel, A. E., Drijvers, J. M., Baker, G. J., Catozzi, A., García-Cañaveras, J. C., Gassaway, B. M., Miller, B. C., Juneja, V. R., Nguyen, T. H., Joshi, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.009 · Cited by 780
Su, S., Liu, Q., Chen, J., Chen, J., Chen, F., He, C., Huang, D., Wu, W., Lin, L., Huang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.021 · Cited by 772
Functional plasticity of macrophages: reversible adaptation to changing microenvironments
Stout, R. D., & Suttles, J. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0504272 · Cited by 751
Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived Cells
Liu, Z., Gu, Y., Chakarov, S., Bleriot, C., Kwok, I., Chen, X., Shin, A., Huang, W., Dress, R. J., Dutertre, C.-A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.009 · Cited by 719
Pombo Antunes, A. R., Scheyltjens, I., Lodi, F., Messiaen, J., Antoranz, A., Duerinck, J., Kancheva, D., Martens, L., De Vlaminck, K., Van Hove, H., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00789-y · Cited by 704
Macrophage diversity in cancer revisited in the era of single-cell omics
Ma, R.-Y., Black, A., & Qian, B.-Z. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.008 · Cited by 698
Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment
Wu, K., Lin, K., Li, X., Yuan, X., Xu, P., Ni, P., & Xu, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01731 · Cited by 687
Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease
Mulder, K., Patel, A. A., Kong, W. T., Piot, C., Halitzki, E., Dunsmore, G., Khalilnezhad, S., Irac, S. E., Dubuisson, A., Chevrier, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.007 · Cited by 678
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M.-M., Wyckoff, J., Mertz, K. D., Varga, Z., Junt, T., & Bentires-Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 665
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C.-X., & Zhu, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02327-z · Cited by 657
Müller, S., Kohanbash, G., Liu, S. J., Alvarado, B., Carrera, D., Bhaduri, A., Watchmaker, P. B., Yagnik, G., Di Lullo, E., Malatesta, M., et al. (2017) · Genome Biology · doi:10.1186/s13059-017-1362-4 · Cited by 654 · cited 5×
“Ontogeny, and not just external stimuli, has been established as an important contributing factor to how macrophages respond to physiologic and pathologic stimuli, underlying the importance of further understanding in this area (43, 44).”
InfluentialMetabolic reprogramming in macrophage responses
Liu, Y., Xu, R., Gu, H., Zhang, E., Qu, J., Cao, W., Huang, X., Yan, H., He, J., & Cai, Z. (2021) · Biomarker Research · doi:10.1186/s40364-020-00251-y · Cited by 641 · cited 1×
“Arginine metabolism Metabolizes arginine by iNOS to NO and L-citrulline (54, 56) Hydrolyzes arginine by arginase to orthenine and urea (54, 56)”
BackgroundMacrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies
Bowman, R. L., Klemm, F., Akkari, L., Pyonteck, S. M., Sevenich, L., Quail, D. F., Dhara, S., Simpson, K., Gardner, E. E., Iacobuzio-Donahue, C. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.052 · Cited by 619 · cited 1×
“Even in protected spaces such as the central nervous system, both MDMs and tissue-resident microglia with distinct transcriptional profiles and functions are represented in the population of TAMs in primary brain tumors (43, 87).”
BackgroundTumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Bi, K., He, M. X., Bakouny, Z., Kanodia, A., Napolitano, S., Wu, J., Grimaldi, G., Braun, D. A., Cuoco, M. S., Mayorga, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.015 · Cited by 618
Obstacles and opportunities for understanding macrophage polarization
Murray, P. J., & Wynn, T. A. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0710409 · Cited by 563 · cited 1×
“It is worthwhile to note that many polarization experiments have been performed only in mice and have not been fully replicated in humans (47).”
BackgroundKhanna, C., Anderson, P. M., Hasz, D. E., Katsanis, E., Neville, M., & Klausner, J. S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970401)79:7 · Cited by 561
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
Zhang, F., Parayath, N. N., Ene, C. I., Stephan, S. B., Koehne, A. L., Coon, M. E., Holland, E. C., & Stephan, M. T. (2019) · Nature Communications · doi:10.1038/s41467-019-11911-5 · Cited by 521
Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508
Martinez, F. O., Helming, L., Milde, R., Varin, A., Melgert, B. N., Draijer, C., Thomas, B., Fabbri, M., Crawshaw, A., Ho, L. P., et al. (2013) · Blood · doi:10.1182/blood-2012-06-436212 · Cited by 507
Metabolism of tissue macrophages in homeostasis and pathology
Wculek, S. K., Dunphy, G., Heras-Murillo, I., Mastrangelo, A., & Sancho, D. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00791-9 · Cited by 501 · cited 1×
“acids, and lipids increases the availability of critical nutrients such as iron in the TME, contributes to immunosuppression, and provides strong growth signals to cancer cells (55, 104).”
BackgroundChen, D., Xie, J., Fiskesund, R., Dong, W., Liang, X., Lv, J., Jin, X., Liu, J., Mo, S., Zhang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03225-9 · Cited by 489
Steggerda, S. M., Bennett, M. K., Chen, J., Emberley, E., Huang, T., Janes, J. R., Li, W., MacKinnon, A. L., Makkouk, A., Marguier, G., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0308-4 · Cited by 476 · cited 2×
“CB-1158, a small molecule developed to inhibit arginine metabolism and reverse immunosuppression in the TME, has entered phase I/II trials alone and in combination with checkpoint inhibitors (105, 254).”
BackgroundSTAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445
Endotoxin and Double Stranded RNA render Macrophages Cytotoxic
ALEXANDER, P., & EVANS, R. (1971) · Nature New Biology · doi:10.1038/newbio232076a0 · Cited by 438
Wanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420
Genard, G., Lucas, S., & Michiels, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00828 · Cited by 419
Cellular backpacks for macrophage immunotherapy
Shields, C. W., Evans, M. A., Wang, L. L.-W., Baugh, N., Iyer, S., Wu, D., Zhao, Z., Pusuluri, A., Ukidve, A., Pan, D. C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6579 · Cited by 414
Metchnikoff and the phagocytosis theory
Tauber, A. I. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1244 · Cited by 413
Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 412
Systematic validation of specific phenotypic markers for in vitro polarized human macrophages
Ambarus, C. A., Krausz, S., van Eijk, M., Hamann, J., Radstake, T. R. D. J., Reedquist, K. A., Tak, P. P., & Baeten, D. L. P. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.10.013 · Cited by 411
Vasandan, A. B., Jahnavi, S., Shashank, C., Prasad, P., Kumar, A., & Prasanna, S. J. (2016) · Scientific Reports · doi:10.1038/srep38308 · Cited by 406 · cited 1×
“Other groups have investigated mesenchymal stem cell-activated macrophages as a distinct phenotype as well (67, 68).”
BackgroundFetal monocytes and the origins of tissue-resident macrophages
Hoeffel, G., & Ginhoux, F. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.001 · Cited by 401
Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400
Epigenetic regulation of macrophage polarization and function
Ivashkiv, L. B. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.001 · Cited by 396 · cited 5×
“Function Infectious/Th1 response, type 1 inflammation, intracellular pathogen killing, tumor resistance (46, 54, 60) Allergy/Th2 response, parasite killing, immunoregulation, matrix deposition, tissue repair, tumor promotion (46, 54, 60)”
BackgroundInfluentialFerrante, C. J., Pinhal-Enfield, G., Elson, G., Cronstein, B. N., Hasko, G., Outram, S., & Leibovich, S. J. (2013) · Inflammation · doi:10.1007/s10753-013-9621-3 · Cited by 375
Ontogeny of Tissue-Resident Macrophages
Hoeffel, G., & Ginhoux, F. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00486 · Cited by 364 · cited 2×
“Subsequent waves of cells from the yolk sac and fetal liver seed resident macrophages in most tissues (34).”
BackgroundWang, H., Tian, T., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168470 · Cited by 364
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer
Kersten, K., Hu, K. H., Combes, A. J., Samad, B., Harwin, T., Ray, A., Rao, A. A., Cai, E., Marchuk, K., Artichoker, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.05.004 · Cited by 349
Zhao, X., Qu, J., Sun, Y., Wang, J., Liu, X., Wang, F., Zhang, H., Wang, W., Ma, X., Gao, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15736 · Cited by 345
Zhang, R., Qi, F., Zhao, F., Li, G., Shao, S., Zhang, X., Yuan, L., & Feng, Y. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1435-2 · Cited by 343 · cited 1×
“Cancer-associated fibroblasts recruit TAMs, support M2 polarization, and inhibit cancer fighting immune cells from entering the TME (107, 108).”
BackgroundRodriguez-Garcia, A., Lynn, R. C., Poussin, M., Eiva, M. A., Shaw, L. C., O’Connor, R. S., Minutolo, N. G., Casado-Medrano, V., Lopez, G., Matsuyama, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20893-2 · Cited by 341
Major pathways involved in macrophage polarization in cancer
Kerneur, C., Cano, C. E., & Olive, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026954 · Cited by 337 · cited 1×
“While some TAMs can display anti-tumor properties such as phagocytizing tumor cells and orchestrating an immune response, most macrophages in the tumor microenvironment are protumorigenic (8).”
BackgroundTissue‐resident macrophages: then and now
Davies, L. C., & Taylor, P. R. (2015) · Immunology · doi:10.1111/imm.12451 · Cited by 334
The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion
Mojic, M., Takeda, K., & Hayakawa, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010089 · Cited by 334
Cooperation of Immune Lymphoid Cells with Macrophages in Tumour Immunity
EVANS, R., & ALEXANDER, P. (1970) · Nature · doi:10.1038/228620a0 · Cited by 333 · cited 1×
“Peter Alexander and Robert Evans did significant early work with macrophages at the Institute of Cancer Research in London, demonstrating that macrophages could be “armed” and made cytotoxic by exposure to specially sensitized lymphoid cells (13, 49).”
BackgroundDas reticulo-endotheliale System
Aschoff, L. (1924) · Ergebnisse der Inneren Medizin und Kinderheilkunde · doi:10.1007/978-3-642-90639-8_1 · Cited by 333 · cited 1×
“The mononuclear phagocyte system was therefore coined in 1969 as an updated classification scheme, comprised of monocytes and monocyte-derived macrophages (15, 19, 20).”
BackgroundThe Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332
Nishijima, T. F., Muss, H. B., Shachar, S. S., Tamura, K., & Takamatsu, Y. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.10.003 · Cited by 324
Tumour macrophages as potential targets of bisphosphonates
Rogers, T. L., & Holen, I. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-177 · Cited by 324
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30532-5 · Cited by 307
Molecular Repolarisation of Tumour-Associated Macrophages
Van Dalen, F. J., Van Stevendaal, M. H. M. E., Fennemann, F. L., Verdoes, M., & Ilina, O. (2018) · Molecules · doi:10.3390/molecules24010009 · Cited by 302
Bergman, P. J., Camps-Palau, M. A., McKnight, J. A., Leibman, N. F., Craft, D. M., Leung, C., Liao, J., Riviere, I., Sadelain, M., Hohenhaus, A. E., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.027 · Cited by 298
Macrophages of distinct origins contribute to tumor development in the lung
Loyher, P.-L., Hamon, P., Laviron, M., Meghraoui-Kheddar, A., Goncalves, E., Deng, Z., Torstensson, S., Bercovici, N., Baudesson de Chanville, C., Combadière, B., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180534 · Cited by 298 · cited 1×
“For example, in a mouse model of lung carcinoma, TRMs were associated with tumor cell growth, while recruited MDMs were more associated with metastasis (86).”
BackgroundInhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species
Kusmartsev, S., & Gabrilovich, D. I. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0103010 · Cited by 292
Alternatively activated macrophages; a double-edged sword in allergic asthma
Abdelaziz, M. H., Abdelwahab, S. F., Wan, J., Cai, W., Huixuan, W., Jianjun, C., Kumar, K. D., Vasudevan, A., Sadek, A., Su, Z., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02251-w · Cited by 287 · cited 1×
“While the general behavior of these subtypes is largely consistent across experiments, it is easy to find discrepancies in the literature regarding stimuli, markers and secretory products attributed to each (69, 70).”
BackgroundMacrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Dewar, A. L., Cambareri, A. C., Zannettino, A. C. W., Miller, B. L., Doherty, K. V., Hughes, T. P., & Lyons, A. B. (2005) · Blood · doi:10.1182/blood-2004-10-3967 · Cited by 284
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Ring, N. G., Herndler-Brandstetter, D., Weiskopf, K., Shan, L., Volkmer, J.-P., George, B. M., Lietzenmayer, M., McKenna, K. M., Naik, T. J., McCarty, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710877114 · Cited by 283
van Rooijen, N., & van Nieuwmegen, R. (1984) · Cell and Tissue Research · doi:10.1007/bf00217308 · Cited by 256
Chen, H.-M., van der Touw, W., Wang, Y. S., Kang, K., Mai, S., Zhang, J., Alsina-Beauchamp, D., Duty, J. A., Mungamuri, S. K., Zhang, B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97570 · Cited by 253
The hematopoietic stem cell niche: from embryo to adult
Gao, X., Xu, C., Asada, N., & Frenette, P. S. (2018) · Development · doi:10.1242/dev.139691 · Cited by 247
Lamb, Y. N. (2019) · Drugs · doi:10.1007/s40265-019-01210-0 · Cited by 242
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Sloas, C., Gill, S., & Klichinsky, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783305 · Cited by 241
Ontogeny of Tumor-Associated Macrophages
Laviron, M., & Boissonnas, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01799 · Cited by 239 · cited 1×
“There are differing accounts of the ontogeny of TAMs; both MDMs and TRMs are likely recruited by tumors to varying degrees (82).”
BackgroundHu, G., Guo, M., Xu, J., Wu, F., Fan, J., Huang, Q., Yang, G., Lv, Z., Wang, X., & Jin, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01998 · Cited by 237
Ge, Z., & Ding, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590941 · Cited by 222 · cited 1×
“Each of these processes are complex, and detailed reviews have been written (96, 102, 103).”
BackgroundInhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages.
Fidler, I. J. (1974) · PubMed · Cited by 211
Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide
Lee, C., Jeong, H., Bae, Y., Shin, K., Kang, S., Kim, H., Oh, J., & Bae, H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0610-4 · Cited by 211
Dallavalasa, S., Beeraka, N. M., Basavaraju, C. G., Tulimilli, S. V., Sadhu, S. P., Rajesh, K., Aliev, G., & Madhunapantula, S. V. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210720143721 · Cited by 210 · cited 2×
“In cancer, most tumor-associated immune cells are macrophages, coined tumor-associated macrophages (TAMs) (7).”
BackgroundBisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
Van Acker, H. H., Anguille, S., Willemen, Y., Smits, E. L., & Van Tendeloo, V. F. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.008 · Cited by 206
Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results
Cluff, C. W. (2009) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-1603-7_10 · Cited by 205
The Ontogeny of Monocyte Subsets
Wolf, A. A., Yáñez, A., Barman, P. K., & Goodridge, H. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01642 · Cited by 201 · cited 5×
“Dendritic cells (DCs) would shortly be recognized as distinct cells in the mononuclear phagocyte system as well (21).”
BackgroundInfluentialYan, D., Wang, H.-W., Bowman, R. L., & Joyce, J. A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.035 · Cited by 194
CCL2 Blockade Augments Cancer Immunotherapy
Fridlender, Z. G., Buchlis, G., Kapoor, V., Cheng, G., Sun, J., Singhal, S., Crisanti, M. C., Wang, L.-C. S., Heitjan, D., Snyder, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2326 · Cited by 193
Tumour-Associated Macrophages (TAMs) in Colon Cancer and How to Reeducate Them
Yahaya, M. A. F., Lila, M. A. M., Ismail, S., Zainol, M., & Afizan, N. A. R. N. M. (2019) · Journal of Immunology Research · doi:10.1155/2019/2368249 · Cited by 187
Schulz, D., Severin, Y., Zanotelli, V. R. T., & Bodenmiller, B. (2019) · Scientific Reports · doi:10.1038/s41598-018-38127-9 · Cited by 185 · cited 1×
“(It is worthwhile to note that although it is widely accepted that M2 macrophages have decreased ability to respond to infectious insults, some conflicting data in the human literature describe M2 macrophages as highly phagocytic (75, 76)).”
BackgroundTyrosine Kinase Inhibitors in Veterinary Medicine
London, C. A. (2009) · Topics in companion animal medicine · doi:10.1053/j.tcam.2009.02.002 · Cited by 183
Gomez-Brouchet, A., Illac, C., Gilhodes, J., Bouvier, C., Aubert, S., Guinebretiere, J.-M., Marie, B., Larousserie, F., Entz-Werlé, N., de Pinieux, G., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331193 · Cited by 179
Adaptation and memory in immune responses
Natoli, G., & Ostuni, R. (2019) · Nature Immunology · doi:10.1038/s41590-019-0399-9 · Cited by 179
Gu, L., Li, H., Chen, L., Ma, X., Li, X., Gao, Y., Zhang, Y., Xie, Y., & Zhang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.7876 · Cited by 178
Mason, N. J., Gnanandarajah, J. S., Engiles, J. B., Gray, F., Laughlin, D., Gaurnier-Hausser, A., Wallecha, A., Huebner, M., & Paterson, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0088 · Cited by 178
Benner, B., Good, L., Quiroga, D., Schultz, T. E., Kassem, M., Carson, W. E., Cherian, M. A., Sardesai, S., & Wesolowski, R. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s253232 · Cited by 177
Thamm, D. H., Kurzman, I. D., King, I., Li, Z., Sznol, M., Dubielzig, R. R., Vail, D. M., & MacEwen, E. G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2510 · Cited by 174
Self-citationEisinger, S., Sarhan, D., Boura, V. F., Ibarlucea-Benitez, I., Tyystjärvi, S., Oliynyk, G., Arsenian-Henriksson, M., Lane, D., Wikström, S. L., Kiessling, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015343117 · Cited by 173
A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages
Feng, Y., Mu, R., Wang, Z., Xing, P., Zhang, J., Dong, L., & Wang, C. (2019) · Nature Communications · doi:10.1038/s41467-019-10354-2 · Cited by 170
Ni, K., Luo, T., Culbert, A., Kaufmann, M., Jiang, X., & Lin, W. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c05039 · Cited by 167
Tumor-Associated Macrophages: A Potential Target for Cancer Therapy
Tan, Y., Wang, M., Zhang, Y., Ge, S., Zhong, F., Xia, G., & Sun, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693517 · Cited by 165
Lascelles, B. D. X., Dernell, W. S., Correa, M. T., Lafferty, M., Devitt, C. M., Kuntz, C. A., Straw, R. C., & Withrow, S. J. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.01.011 · Cited by 164
Maekawa, N., Konnai, S., Takagi, S., Kagawa, Y., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Deguchi, T., Nakajima, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09444-2 · Cited by 164
Metabolism drives macrophage heterogeneity in the tumor microenvironment
Li, S., Yu, J., Huber, A., Kryczek, I., Wang, Z., Jiang, L., Li, X., Du, W., Li, G., Wei, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110609 · Cited by 164 · cited 2×
“Macrophages are the most abundant immune cell in the TME and comprise a strikingly heterogenous group with multiple ontogenies, phenotypes and roles represented (81).”
BackgroundBarnard, R. A., Wittenburg, L. A., Amaravadi, R. K., Gustafson, D. L., Thorburn, A., & Thamm, D. H. (2014) · Autophagy · doi:10.4161/auto.29165 · Cited by 162
Self-citationDistribution and prognostic impact of microglia/macrophage subpopulations in gliomas
Zeiner, P. S., Preusse, C., Golebiewska, A., Zinke, J., Iriondo, A., Muller, A., Kaoma, T., Filipski, K., Müller‐Eschner, M., Bernatz, S., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12690 · Cited by 162
Tissue-Resident Macrophage Development and Function
Wu, Y., & Hirschi, K. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.617879 · Cited by 160 · cited 1×
“the scope of this review; several excellent reviews of macrophage ontogeny and nomenclature are recommended (34, 39).”
BackgroundDirecting cell therapy to anatomic target sites in vivo with magnetic resonance targeting
Muthana, M., Kennerley, A. J., Hughes, R., Fagnano, E., Richardson, J., Paul, M., Murdoch, C., Wright, F., Payne, C., Lythgoe, M. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms9009 · Cited by 156
Belgiovine, C., Bello, E., Liguori, M., Craparotta, I., Mannarino, L., Paracchini, L., Beltrame, L., Marchini, S., Galmarini, C. M., Mantovani, A., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.205 · Cited by 155
Vail, D. M., MacEwen, E. G., Kurzman, I. D., Dubielzig, R. R., Helfand, S. C., Kisseberth, W. C., London, C. A., Obradovich, J. E., Madewell, B. R., & Rodriguez, C. O. (1995) · PubMed · Cited by 152
From the Reticuloendothelial to Mononuclear Phagocyte System – The Unaccounted Years
Yona, S., & Gordon, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00328 · Cited by 149 · cited 3×
“A more comprehensive outline of the history of macrophage research is presented in several good reviews (15, 29).”
BackgroundMaekawa, N., Konnai, S., Ikebuchi, R., Okagawa, T., Adachi, M., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., Murata, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098415 · Cited by 145
MacEwen, E. G., Kurzman, I. D., Vail, D. M., Dubielzig, R. R., Everlith, K. M., Madewell, B. R., Rodriguez, C. O., Phillips, B., Zwahlen, C. H., Obradovich, J. E., et al. (1999) · PubMed · Cited by 134
A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs
Khanna, C., Rosenberg, M. P., & Vail, D. M. (2015) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.12596 · Cited by 132
Igase, M., Nemoto, Y., ITAMOTO, K., Tani, K., NAKAICHI, M., Sakurai, M., Sakai, Y., Noguchi, S., Kato, M., Tsukui, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75533-4 · Cited by 132
Griesmann, H., Drexel, C., Milosevic, N., Sipos, B., Rosendahl, J., Gress, T. M., & Michl, P. (2017) · Gut · doi:10.1136/gutjnl-2015-310049 · Cited by 129
Pang, L., Zhu, Y., Qin, J., Zhao, W., & Wang, J. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1502839 · Cited by 129
Distant Relations: Macrophage Functions in the Metastatic Niche
Doak, G. R., Schwertfeger, K. L., & Wood, D. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.03.011 · Cited by 127
Kawamura, S., Onai, N., Miya, F., Sato, T., Tsunoda, T., Kurabayashi, K., Yotsumoto, S., Kuroda, S., Takenaka, K., Akashi, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.019 · Cited by 126
Guilliams, M., & van de Laar, L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00406 · Cited by 123
Heinrich, F., Lehmbecker, A., Raddatz, B. B., Kegler, K., Tipold, A., Stein, V. M., Kalkuhl, A., Deschl, U., Baumgärtner, W., Ulrich, R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183572 · Cited by 123 · cited 1×
“human and murine macrophage gene sets only had minor overlap with gene sets of the polarized macrophages (72).”
BackgroundTumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer
Xiao, M., He, J., Yin, L., Chen, X., Zu, X., & Shen, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799428 · Cited by 120
Sathe, P., Metcalf, D., Vremec, D., Naik, S. H., Langdon, W. Y., Huntington, N. D., Wu, L., & Shortman, K. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.020 · Cited by 116 · cited 1×
“A bone marrowderived progenitor cell of monocytes, macrophages and DCs was isolated in 2006 in the mouse, although this finding has since been debated in favor of the theory that there is not a common macrophage-dendritic cell precursor (22, 23).”
BackgroundJalil, A. R., Andrechak, J. C., & Discher, D. E. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa006 · Cited by 116
Müller, E., Speth, M., Christopoulos, P. F., Lunde, A., Avdagic, A., Øynebråten, I., & Corthay, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02520 · Cited by 115
Bacillus Calmette–Guerin Immunotherapy for Urothelial Carcinoma of the Bladder
Kresowik, T. P., & Griffith, T. S. (2009) · Immunotherapy · doi:10.2217/1750743x.1.2.281 · Cited by 114
Capturing the Fantastic Voyage of Monocytes Through Time and Space
Teh, Y. C., Ding, J. L., Ng, L. G., & Chong, S. Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00834 · Cited by 114 · cited 2×
“Monocyte-derived macrophages (MDMs) are continually renewed via the bone marrow and spleen during periods of high demand such as inflammation or tissue reparation (28, 30).”
BackgroundTumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities
Andersen, J. K., Miletić, H., & Hossain, J. A. (2022) · Cancers · doi:10.3390/cancers14051319 · Cited by 109
The Extravascular Development of the Monocyte Observed In vivo
Ebert, R., & Florey, H. W. (1939) · PubMed Central · Cited by 107
Haag, G. M., Springfeld, C., Grün, B., Apostolidis, L., Zschäbitz, S., Dietrich, M., Berger, A.-K., Weber, T. F., Zoernig, I., Schaaf, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.017 · Cited by 105
Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment
Mun, J.-Y., Leem, S.-H., Lee, J. H., & Kim, H. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864739 · Cited by 103 · cited 2×
“In hepatocellular carcinoma, for example, tumor-associated neutrophils recruit TAMs and regulatory T cells (Tregs) to the TME, promoting the immunosuppressive environment (110).”
BackgroundPing, L., Ding, N., Shi, Y., Feng, L., Li, J., Liu, Y., Lin, Y., Shi, C., Wang, X., Pan, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16836 · Cited by 101
Shan, H., Dou, W., Zhang, Y., & Qi, M. (2020) · Nanoscale · doi:10.1039/d0nr04520a · Cited by 97
Piao, H., Fu, L., Wang, Y., Liu, Y., Wang, Y., Meng, X., Yang, D., Xiao, X., & Zhang, J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02366-6 · Cited by 96
RENDERING MACROPHAGES SPECIFICALLY CYTOTOXIC BY A FACTOR RELEASED FROM IMMUNE LYMPHOID CELLS
Evans, R., & Alexander, P. M. (1971) · Transplantation · doi:10.1097/00007890-197109000-00015 · Cited by 95 · cited 1×
“Peter Alexander and Robert Evans did significant early work with macrophages at the Institute of Cancer Research in London, demonstrating that macrophages could be “armed” and made cytotoxic by exposure to specially sensitized lymphoid cells (13, 49).”
BackgroundJaggi, U., Yang, M., Matundan, H. H., Hirose, S., Shah, P. K., Sharifi, B. G., & Ghiasi, H. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008971 · Cited by 95 · cited 1×
“(It is worthwhile to note that although it is widely accepted that M2 macrophages have decreased ability to respond to infectious insults, some conflicting data in the human literature describe M2 macrophages as highly phagocytic (75, 76)).”
BackgroundLinehan, D., Noel, M. S., Hezel, A. F., Wang-Gillam, A., Eskens, F., Sleijfer, S., Desar, I. M. E., Erdkamp, F., Wilmink, J., Diehl, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.92 · Cited by 93
Tsung, K., & Norton, J. A. (2006) · Surgical Oncology · doi:10.1016/j.suronc.2006.05.002 · Cited by 92
Regan, D. P., Chow, L., Das, S., Haines, L., Palmer, E., Kurihara, J. N., Coy, J. W., Mathias, A., Thamm, D. H., Gustafson, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2105 · Cited by 92
Self-citationMeyers, P. A., & Chou, A. J. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_17 · Cited by 90
Dai, Q., Xu, M., Yao, M., & Sun, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707454 · Cited by 90
Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy
Bendíčková, K., & Frič, J. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mir0420-055r · Cited by 90
Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89
Langerhans' cell granule. An endocytotic organelle
Hashimoto, K. (1971) · Archives of Dermatology · doi:10.1001/archderm.104.2.148 · Cited by 89
Liguori, M., Buracchi, C., Pasqualini, F., Bergomas, F., Pesce, S., Sironi, M., Grizzi, F., Mantovani, A., Belgiovine, C., & Allavena, P. (2106) · Oncotarget · doi:10.18632/oncotarget.9340 · Cited by 88
Brempelis, K. J., Cowan, C. M., Kreuser, S. A., Labadie, K. P., Prieskorn, B. M., Lieberman, N. A. P., Ene, C., Moyes, K. W., Chinn, H. K., DeGolier, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001356 · Cited by 88
Claassen, I. J. T. M., van Rooijen, N., & Claassen, E. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90376-7 · Cited by 87
Yamada, K., Uchiyama, A., Uehara, A., Perera, B., Ogino, S., Yokoyama, Y., Takeuchi, Y., Udey, M. C., Ishikawa, O., & Motegi, S.-I. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2812 · Cited by 87 · cited 1×
“Mesenchymal stromal cells, in addition to directly promoting tumor progression, secrete various angiogenic factors that polarize TAMs to an M2-like phenotype (109).”
BackgroundEvaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma
U'Ren, L. W., Biller, B. J., Elmslie, R. E., Thamm, D. H., & Dow, S. W. (2007) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2007.tb02936.x · Cited by 86
Self-citationImmune regulation of canine tumour and macrophage PD‐L1 expression
Hartley, G. P., Faulhaber, E. A., Caldwell, A. B., Coy, J., Kurihara, J. N., Guth, A., Regan, D. P., & DOW, S. W. (2016) · Veterinary and Comparative Oncology · doi:10.1111/vco.12197 · Cited by 85 · cited 3×
“The blockade of this checkpoint has been shown to increase tumor cell phagocytosis by PD-1-positive TAMs (113, 324).”
BackgroundInfluentialPD ‐1 expression by canine T cells and functional effects of PD ‐1 blockade
Coy, J., Caldwell, A. B., Chow, L., Guth, A., & DOW, S. W. (2017) · Veterinary and Comparative Oncology · doi:10.1111/vco.12294 · Cited by 85
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples
Scott, E. M., Jacobus, E. J., Lyons, B., Frost, S., Freedman, J. D., Dyer, A., Khalique, H., Taverner, W. K., Carr, A., CHAMPION, B. R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0807-6 · Cited by 85
Ou, W., Stewart, S., White, A. M., Kwizera, E. A., Xu, J., Fang, Y., Shamul, J. G., Xie, C., Nurudeen, S. M., Tirada, N. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36045-7 · Cited by 84
Vellozo, N. S., Pereira-Marques, S. T., Cabral-Piccin, M. P., Filardy, A. A., Ribeiro-Gomes, F. L., Rigoni, T. S., DosReis, G. A., & Lopes, M. F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01560 · Cited by 81
Proton irradiation orchestrates macrophage reprogramming through NFκB signaling
Genard, G., Wéra, A.-C., Huart, C., Calvé, B. L., Penninckx, S., Fattaccioli, A., Tabarrant, T., Demazy, C., Ninane, N., Heuskin, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0757-9 · Cited by 81
Targeted Repolarization of Tumor‐Associated Macrophages via Imidazoquinoline‐Linked Nanobodies
Bolli, E., Scherger, M., Arnouk, S. M., Antunes, A. R. P., Straßburger, D., Urschbach, M., Stickdorn, J., Vlaminck, K. D., Movahedi, K., Räder, H. J., et al. (2021) · Advanced Science · doi:10.1002/advs.202004574 · Cited by 80
Opperman, K. S., Vandyke, K., Clark, K. C., Coulter, E. A., Hewett, D. R., Mrozik, K. M., Schwarz, N., Evdokiou, A., Croucher, P. I., Psaltis, P. J., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.05.006 · Cited by 78
The yin and yang of imaging tumor associated macrophages with PET and MRI
Mukherjee, S., Sonanini, D., Maurer, A., & Daldrup-Link, H. E. (2019) · Theranostics · doi:10.7150/thno.37306 · Cited by 78
Paasch, D., Meyer, J., Σταμοπούλου, Α., Lenz, D., Kuehle, J., Kloos, D., Buchegger, T., Holzinger, A., Falk, C. S., Kloth, C., et al. (2022) · Cells · doi:10.3390/cells11060994 · Cited by 76
Research works printed but not linked: 2
- Macewen EG Kurzman ID Helfand S Vail D London C Kisseberth W. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: A progress review*. J Drug Target (1994) 2: 391–6. doi: 10.3109/10611869408996814 7704483 · DOI · Paper page
- Gordon SR Maute RL Dulken BW Hutter G George BM McCracken MN. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity. Nature (2017) 545: 495. doi: 10.1038/NATURE22396 28514441 PMC5931375 · DOI · Paper page
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Moreover, engineered CAR-Ms have leaded to increase of anti-tumor cytokines, such as IL-6, and chemokines, such as CXCL18, in the TME of osteosarcoma [138, 139].”
BackgroundTumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy
Saeed, A. F. U. H. (2025) · Cells · doi:10.3390/cells14100741 · Cited by 112
“Macrophages express dissociated CRT, forming the CRT/CD91/C1q complexes, allowing them to phagocytose cancer cells [109].”
Shao, S., Miao, H., & Ma, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295684 · Cited by 70
Mengistu, B. A., Tsegaw, T., Demessie, Y., Getnet, K., Bitew, A. B., Kinde, M. Z., Berihun, A. M., Mebratu, A. S., Mekasha, Y. T., Feleke, M. G., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03558-0 · Cited by 85
Targeting Macrophage Polarization for Reinstating Homeostasis following Tissue Damage
Du, Q., Dickinson, A., Nakuleswaran, P., Maghami, S., Alagoda, S., Hook, A. L., & Ghaemmaghami, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137278 · Cited by 60
“The recognition of macrophages in regulating these processes has underpinned the emergence of many approaches focused on rebalancing immune homeostasis to support tissue repair by targeting macrophage polarization to enhance immune-mediated tissue regeneration [17,21–30].”
Background
Metadata
- Authors
- Brady, R. V., & Thamm, D. H.
- Affiliations
- Colorado State University (US)
- Corresponding author
- Thamm, Douglas H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-04-05
- Volume
- 14
- Pages
- 1176807-1176807
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC10113558
- OpenAlex
- W4362637748
- Cited by
- 35
- References
- 329
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 14 · 2023: 2
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- American Kennel Club Canine Health Foundation (03033-E)
- Morris Animal Foundation (D22CA-500)
- National Institutes of Health (2T32OD010437-21)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- tumor-associated macrophages, macrophage plasticity, tumor microenvironment, immunosuppression, pet dogs, dogs as cancer models, macrophage phenotype, macrophage origin
- MeSH terms
- Tumor-Associated Macrophages, Animals, Dogs, Humans, Macrophages, Neoplasms, Prognosis, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.